N/A
N=148
Implementation of Genomics in Substance Use Disorder Treatment
Tobacco Use Disorder · Smoking Cessation · Tobacco Use Cessation
Bottom Line
View on ClinicalTrials.gov: NCT04768114 ↗Enrolled (actual)
148
Serious AEs
0.0%
Results posted
Jan 2024
Primary outcome: Primary: Change in Use of Smoking Cessation Pharmacotherapy in Past 30 Days — 11; 9; 9; 2 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Genetically-Informed RiskProfile (Behavioral); Brief Cessation Advice (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Washington University School of Medicine
- Primary completion
- Dec 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Use of Smoking Cessation Pharmacotherapy in Past 30 Days |
11; 9; 9; 2; 16; 8 | — |
| PRIMARY Change in Number of Cigarettes Smoked Per Day |
13.1; 12.3; 12.0; 11.5; 9.2; 9.7 | — |
| SECONDARY Change in Readiness to Quit Smoking |
16; 22; 45; 37; 13; 15 | — |
| SECONDARY Change in Perceived Disease Risk |
4.5; 4.3; 4.7; 4.3; 4.6; 4.4 | — |
| SECONDARY Change in Perceived Benefits of Cessation |
4.2; 4.2; 4.2; 4.2; 4.6; 4.4 | — |
| SECONDARY Change in Perceived Value of Cessation Treatments |
3.0; 3.0; 3.3; 2.9; 3.2; 2.9 | — |
| SECONDARY Change in Self-efficacy of Cessation |
3.5; 3.5; 3.6; 3.7; 3.8; 3.9 | — |
| SECONDARY Personal Relevance of Intervention |
4.5; 3.7 | — |
Summary
Cigarette smoking remains one of the leading causes of preventable death. Effective smoking cessation medications exist but use of these treatments is low, making it difficult for most to quit smoking. Behavioral interventions are needed to engage current smokers in the process of quitting smoking and promote the use of evidence-based cessation medications.
At the same time, genetics influences one's smoking behaviors (e.g., how much they smoke, difficulty quitting) and risk of smoking-related diseases, yet these personalized factors have not been included in existing behavioral interventions. Incorporating these individualized factors into smoking cessation interventions may make them more personally engaging and thus motivating for treatment.
This study will pilot test a risk communication tool that is personalized to one's genetics and will demonstrate the feasibility of a larger trial to test the effect of this personalized genetically-informed intervention on smoking cessation.
Eligibility Criteria
Inclusion Criteria
- At least 18 years of age
- Smoked combustible cigarettes in past 30 days
- Computer access for remote-based study visits
Exclusion Criteria
- Younger than 18 years of age
- No computer access
Data sourced from ClinicalTrials.gov (NCT04768114). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.